[Usefulness of support during treatment by alignment with health centers and DOT during hospitalization].
OBJECTIVE
To evaluate the effectiveness of patient support by alignment with public health centers and DOT during hospitalization, on treatment completion of tuberculosis patients.


METHODS
Four hundred seventy-seven patients (male 344, female 133) newly admitted from July 1, 2002 to June 30, 2003 to our hospital were enrolled in the study.


METHODS
The patients were divided into two groups: one comprised of the patients who were discussed in the conference held by the hospital staffs and the regional public health center staffs about the necessity of support for continuing treatment regularly after discharge from our hospital (Conference (+) group; N=306), and the other who were not discussed in the conference (Conference (-) group; N=171). The Conference (+) group was further divided into two groups: One comprised of the patients who were regarded to need support after discharge (Support (+) group; N=106), and the other no need of support after discharge (Support (-) group; N=200). The patients' characteristics and backgrounds were compared between the Conference (+) and the Conference (-) groups, and between the Support (+) and the Support (-) groups. The rate of treatment completion and of default were compared between the Conference (+) and the Conference (-) group, and between the Support (+) and the Support (-) group. They were also compared between the patients with and without DOT for a month during hospitalization, and between the patients who were treated for the first time (new case) and those who had been treated previously (retreated case) or who had been treated when they were admitted to our hospital and continued treatment after admission (continuous cases).


RESULTS
There is no significant differences in patients' characteristics and backgrounds between the Conference (+) and Conference (-) groups, but the ratios of male, sputum-culture positivity, far advanced lesions on chest X-ray, hypoalbuminemia, and disemployment were higher in Support (+) group than in Support (-) group. The overall (N=477) treatment outcomes were as follows: cured (defined by sputum-culture negativity at completion of chemotherapy) 300 (62.9%), completed (defined by no sputum data at completion of chemotherapy) 90 (18.9%), failed 5 (1.0%), defaulted 6 (1.3%), transfer out 6 (1.3%) and death 70 (14.7%). Therefore, the ratio of treatment success (defined by cured+completed) was 390/477 (81.8%). Because of more died cases in Conference (-) groups, treatment success rate was significantly higher in the Conference (+) groups than in the Conference (-) groups. There were no significant differences in the rate of treatment success and of default between the Support (+) and the Support (-) groups, but no defaulter case was seen in the Support (+) group. There were no differences in the rate of treatment success and of default between the groups with and without DOT for a month during hospitalization. There were no differences in the rate of treatment success and of default between the groups with the retreated and continuously treated cases and the new cases.


CONCLUSIONS
Treatment success rate was excellent in our study. DOT for a month during hospitalization didn't affect the improvement of treatment success after discharge, partly because the education on tuberculosis treatment was sufficiently done for most patients during hospitalization and a nurse made a telephone call to the patient who didn't attend the outpatient department of the hospital.


CONCLUSIONS
To hold conference with regional public health center is effective for completion of tuberculosis treatment.
Department of Respiratory Disease, Tokatsu Hospital, 409 Shimohanawa, Nagareyama-shi, Chiba 270-0174, Japan. hoshinokeiichi@hotmail.com
Keiichi
K
Hoshino
Kazuko
K
Machida
Yoshiko
Y
Kawabe
Maki
M
Miyamoto
Hiromichi
H
Hara
Wakana
W
Saitou
Michihiro
M
Hirama
Junko
J
Suzuki
Kimihiko
K
Masuda
Motoo
M
Baba
Atsuhisa
A
Tamura
Hideaki
H
Nagai
Naohiro
N
Nagayama
Shinobu
S
Akagawa
Atsuyuki
A
Kurashima
Hideaki
H
Yotsumoto
D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003151:Community Health Centers; D003226:Congresses as Topic; D023801:Directly Observed Therapy; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents